Tanja Fehm

Summary

Country: Germany

Publications

  1. doi request reprint HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial
    Tanja Fehm
    Department of Gynecology and Obstetrics, University of Tubingen, Calwer Strasse 7, 72076, Tubingen, Germany
    Breast Cancer Res Treat 124:403-12. 2010
  2. pmc Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
    Tanja Fehm
    Department of Gynecology and Obstetrics, Calwer Strasse 7, University Hospital of Tuebingen, D 72076 Tuebingen, Germany
    Breast Cancer Res 11:R59. 2009
  3. doi request reprint Hematogenous and lymphatic tumor cell dissemination may be detected in patients diagnosed with ductal carcinoma in situ of the breast
    Malgorzata Banys
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstrasse 7, 72076, Tuebingen, Germany
    Breast Cancer Res Treat 131:801-8. 2012
  4. ncbi request reprint Changes in tumour biological markers during primary systemic chemotherapy (PST)
    Hans Neubauer
    Department of Gynaecology and Obstetrics, University of Tubingen, Tubingen, Germany
    Anticancer Res 28:1797-804. 2008
  5. doi request reprint Bone marrow versus sentinel lymph node involvement in breast cancer: a comparison of early hematogenous and early lymphatic tumor spread
    Andreas D Hartkopf
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwer Strasse 7, 72076 Tuebingen, Germany
    Breast Cancer Res Treat 131:501-8. 2012
  6. doi request reprint Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer
    Tanja Fehm
    Department of Gynecology and Obstetrics, University Hospital Dusseldorf, University of Dusseldorf, Germany
    Int J Gynecol Cancer 23:839-45. 2013
  7. pmc Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells
    Sabine Kasimir-Bauer
    Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg Essen, D 45122 Essen, Germany
    Breast Cancer Res 14:R15. 2012
  8. doi request reprint Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients
    Bahriye Aktas
    Department of Gynecology and Obstetrics, University of Essen, Hufelandstrase 55, 45122 Essen, Germany
    Gynecol Oncol 122:356-60. 2011
  9. pmc Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients
    Bahriye Aktas
    Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg Essen, Hufelandstrasse 55, 45122 Essen, Germany
    Breast Cancer Res 11:R46. 2009
  10. doi request reprint Membrane-receptor initiated proliferative effects of dienogest in human breast cancer cells
    Helen Schneck
    University Women s Hospital, Tubingen, Germany
    Gynecol Endocrinol 29:160-3. 2013

Collaborators

Detail Information

Publications33

  1. doi request reprint HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial
    Tanja Fehm
    Department of Gynecology and Obstetrics, University of Tubingen, Calwer Strasse 7, 72076, Tubingen, Germany
    Breast Cancer Res Treat 124:403-12. 2010
    ..Therefore, it will be mandatory to correlate the assay-dependent HER2 status of CTCs to the clinical response on HER2-targeted therapies...
  2. pmc Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
    Tanja Fehm
    Department of Gynecology and Obstetrics, Calwer Strasse 7, University Hospital of Tuebingen, D 72076 Tuebingen, Germany
    Breast Cancer Res 11:R59. 2009
    ....
  3. doi request reprint Hematogenous and lymphatic tumor cell dissemination may be detected in patients diagnosed with ductal carcinoma in situ of the breast
    Malgorzata Banys
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstrasse 7, 72076, Tuebingen, Germany
    Breast Cancer Res Treat 131:801-8. 2012
    ..The clinical relevance of these cells has to be further evaluated...
  4. ncbi request reprint Changes in tumour biological markers during primary systemic chemotherapy (PST)
    Hans Neubauer
    Department of Gynaecology and Obstetrics, University of Tubingen, Tubingen, Germany
    Anticancer Res 28:1797-804. 2008
    ..The influence of primary systemic therapy (PST) on the expression of relevant therapeutic markers is still under investigation...
  5. doi request reprint Bone marrow versus sentinel lymph node involvement in breast cancer: a comparison of early hematogenous and early lymphatic tumor spread
    Andreas D Hartkopf
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwer Strasse 7, 72076 Tuebingen, Germany
    Breast Cancer Res Treat 131:501-8. 2012
    ..Conversely, a high correlation between nodal status and tumor size, histology, ER-status and lymph vessel invasion was found. Hematogenous and lymphatic tumor spread seem to be because of independent pathways of cancer progression...
  6. doi request reprint Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer
    Tanja Fehm
    Department of Gynecology and Obstetrics, University Hospital Dusseldorf, University of Dusseldorf, Germany
    Int J Gynecol Cancer 23:839-45. 2013
    ..Recent studies demonstrated that DTCs may serve as a prognostic factor in ovarian cancer. The aim of this 3-center study was to evaluate the impact of BM status on survival in a large cohort of patients with ovarian cancer...
  7. pmc Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells
    Sabine Kasimir-Bauer
    Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg Essen, D 45122 Essen, Germany
    Breast Cancer Res 14:R15. 2012
    ..Data were correlated with the presence of disseminated tumor cells (DTC) in the bone marrow (BM) and with clinicopathological data of the patients...
  8. doi request reprint Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients
    Bahriye Aktas
    Department of Gynecology and Obstetrics, University of Essen, Hufelandstrase 55, 45122 Essen, Germany
    Gynecol Oncol 122:356-60. 2011
    ..It was the purpose of the present study (1) to reevaluate the ER/PR expression by CTCs and (2) to compare the hormone receptor status expression profile of CTCs with the primary tumor...
  9. pmc Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients
    Bahriye Aktas
    Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg Essen, Hufelandstrasse 55, 45122 Essen, Germany
    Breast Cancer Res 11:R46. 2009
    ....
  10. doi request reprint Membrane-receptor initiated proliferative effects of dienogest in human breast cancer cells
    Helen Schneck
    University Women s Hospital, Tubingen, Germany
    Gynecol Endocrinol 29:160-3. 2013
    ..Data on breast cancer risk are currently not available. Progesterone receptor membrane component 1 (PGRMC1) is highly expressed in tissues of breast cancer patients and has already been proposed as a predictor for breast cancer risk...
  11. ncbi request reprint Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients
    Sven Becker
    Department of Gynecology and Obstetrics, Tubingen University Hospital, Calwerstr 7, 72076 Tubingen, Germany
    Breast Cancer Res Treat 106:239-43. 2007
    ..The aim of this study was to investigate the status of tumor cell dissemination after primary systemic therapy in relation to therapy response...
  12. doi request reprint Prevalence and prognostic value of disseminated tumor cells in primary endometrial, cervical and vulvar cancer patients
    Christina Barbara Walter
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwer Strasse 7, 72076 Tuebingen, Germany
    Future Oncol 10:41-8. 2014
    ..In contrast to breast cancer, DTCs that derive from cervical, endometrial or vulvar cancer have less potential to initiate metastatic regrow. The molecular mechanisms underlying this observation warrant further investigation. ..
  13. doi request reprint Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial
    Malgorzata Banys
    Department of Gynecology and Obstetrics, Heinrich Heine University of Dusseldorf, Moorenstr, 5, 40225, Dusseldorf, Germany
    BMC Cancer 13:480. 2013
    ..This controlled randomized open-label multi-center study aimed to investigate the influence of zoledronic acid (ZOL) on DTC and survival of breast cancer patients (Clinical Trial Registration Number: NCT00172068)...
  14. pmc Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay
    Tanja Fehm
    Department of Obstetrics and Gynecology, University of Tubingen, Calwerstr 7 6, 72076, Tubingen, Germany
    BMC Cancer 12:308. 2012
    ..The purpose of this study was to compare the antitumor effect of Zol with standard chemotherapy in primary breast cancer cells using ATP-tumor chemosensitivity assay (ATP-TCA)...
  15. doi request reprint Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: experience and lessons learned
    Ingmar Königsrainer
    Department of General, Visceral and Transplant Surgery, Comprehensive Cancer Center, University of Tubingen, Hoppe Seyler Strasse 3, 72076 Tubingen, Germany
    Langenbecks Arch Surg 396:1077-81. 2011
    ..De novo cytoreductive surgery is crucial with the potential to improve prognosis, especially when combined with hyperthermic intraperitoneal chemotherapy (HIPEC)...
  16. doi request reprint Optimal treatment for patients with ectopic pregnancies and a history of fertility-reducing factors
    Sven Becker
    Women s University Hospital, Tubingen University, Calwerstrasse 7, Tubingen, Germany
    Arch Gynecol Obstet 283:41-5. 2011
    ..The aim of this study was to evaluate long-term reproductive outcome after salpingotomy versus salpingectomy in patients with and without additional fertility-reducing factors...
  17. ncbi request reprint Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy
    Sven Becker
    Department of Gynecology and Obstetrics, University Hospital Tubingen, Tubingen, Germany
    Breast Cancer Res Treat 97:91-6. 2006
    ..020). Adjuvant treatment regimens are not able to completely eliminate cytokeratin-positive cells from the bone marrow. Prospective studies need to evaluate, whether these cells could become targets for additional adjuvant therapy...
  18. doi request reprint Influence of pregnancy on bone density: a risk factor for osteoporosis? Measurements of the calcaneus by ultrasonometry
    Bernhard Kraemer
    University Hospital for Women, University of Tuebingen, Calwerstr 7, 72076 Tuebingen, Germany
    Arch Gynecol Obstet 285:907-12. 2012
    ..The study aim was to investigate whether there is a significant alteration in maternal bone density during normal pregnancy...
  19. doi request reprint HER2-positive DTCs/CTCs in breast cancer
    Andreas D Hartkopf
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwer Strasse 7, 72076, Tuebingen, Germany
    Recent Results Cancer Res 195:203-15. 2012
    ..Phenotyping of CTCs/DTCs will thus help to understand mechanism of resistance to HER2-directed therapy. Moreover, patients that are likely to benefit from HER2-directed therapy despite a HER2-negative primary tumor might be identified. ..
  20. pmc The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer
    Michael Eichbaum
    University of Heidelberg Medical School, Department of Gynecology and Obstetrics, Voss Str, 9, 69115 Heidelberg, Germany
    BMC Cancer 11:453. 2011
    ..A combined therapy consisting of pazopanib and metronomic oral cyclophosphamide may offer a well-tolerable treatment option to patients with recurrent, pretreated EOC...
  21. ncbi request reprint Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer
    Andreas D Hartkopf
    Department of Obstetrics and Gynaecology, University of Tuebingen, Calwer Strasse 7, 72076 Tuebingen, Germany
    Anticancer Res 31:979-84. 2011
    ..The aim of this study was to investigate whether changing CTC levels during the course of chemotherapy treatment would also be useful in monitoring response to treatment...
  22. ncbi request reprint Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer
    Pauline Wimberger
    Department of Gynecology and Obstetrics, University of Duisburg Essen, Hufelandstrasse 55, D 45122 Essen, Germany
    Gynecol Oncol 107:331-8. 2007
    ....
  23. ncbi request reprint A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation
    Tanja Fehm
    Department of Obstetrics and Gynecology, University of Tubingen, Tubingen, Germany
    Cancer 107:885-92. 2006
    ....
  24. doi request reprint Lower extremity compartment syndrome after laparoscopic radical hysterectomy: brief report of an unusual complication of laparoscopic positioning requirements
    Barbara Lawrenz
    Tübingen University Women s Hospital, Tubingen University, Department of Surgery, Tubingen, Germany
    J Minim Invasive Gynecol 18:531-3. 2011
    ..We present a case report and review of the existing literature and discuss the main clinical features as well as preventive and therapeutic options...
  25. doi request reprint Mammotome versus ATEC: a comparison of two breast vacuum biopsy techniques under sonographic guidance
    Markus Hahn
    Department for Obstetrics and Gynecology, University Hospital of Tuebingen, Calwerstr 7, 72076, Tubingen, Germany
    Arch Gynecol Obstet 281:287-92. 2010
    ..The study evaluates the differences between the Mammotome (MT) and ATEC (A) vacuum biopsy (VB) of the breast in terms of diagnostic reliability, biopsy duration and complications...
  26. ncbi request reprint Acute twin-twin transfusion syndrome: a case report
    Sven Becker
    Women s Hospital, Institute of Pathology, Tubingen University, Tubingen, Germany
    J Reprod Med 52:953-5. 2007
    ..Antepartum cases of acute TTTS are infrequently described in the literature despite the presence of vascular anastomoses in most monochorionic placentas...
  27. ncbi request reprint Breast cancer proteomics by laser capture microdissection, sample pooling, 54-cm IPG IEF, and differential iodine radioisotope detection
    Hans Neubauer
    University Women s Hospital, Tubingen, Germany
    Electrophoresis 27:1840-52. 2006
    ..This study demonstrates the potential of ProteoTope and LCM to enable extremely sensitive and precise differential analyses from well-defined primary clinical specimen...
  28. doi request reprint Small cell carcinoma of vulva: curative multimodal treatment in face of resistance to initial standard chemotherapy
    Franziska Eckert
    Department of Radiooncology, Eberhard Karls University of Tubingen, Tubingen, Germany
    Strahlenther Onkol 186:521-4. 2010
    ..However, of five reported cases of vulvar manifestation only one patient was disease-free at the time of publication with limited follow-up...
  29. pmc Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance
    Tanja Fehm
    Department of Gynecology and Obstetrics, University Tübingen, Tubingen, Germany
    Breast Cancer Res 10:S1. 2008
    ..In addition, understanding tumor 'dormancy' and identifying metastatic stem cells might result in the development of new therapeutic concepts...
  30. doi request reprint ATP chemosensitivity testing of new antitumor duplex drugs linking 3`-C-ethynylycytidine (ECyd) and 2´-deoxy-5-fluorouridine (5-FdU) in comparison to standard cytostatica and combinations thereof
    Sarah Schott
    Medical School, Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, 69115, Germany
    Invest New Drugs 29:506-13. 2011
    ....
  31. doi request reprint Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma--evaluation by using antimüllerian hormone and retrieved oocytes
    Barbara Lawrenz
    University Women s Hospital, Department of Gynaecological Endocrinology and Reproductive Medicine, Tubingen, Germany
    Fertil Steril 98:141-4. 2012
    ..To study whether the ovarian reserve in female lymphoma patients is already reduced before the start of chemotherapy...
  32. doi request reprint Oncolytic virotherapy of gynecologic malignancies
    Andreas D Hartkopf
    Department of Obstetrics and Gynaecology, University of Tuebingen, Calwer Strasse 7, 72076 Tuebingen, Germany
    Gynecol Oncol 120:302-10. 2011
    ..Here, we provide an overview of different OVs currently being used for virotherapy of gynecologic cancers and discuss challenges and implications for their future development...
  33. ncbi request reprint Her2 expression on disseminated tumor cells from bone marrow of breast cancer patients
    Sven Becker
    Tubingen University Hospital, Department of Gynecology and Obstetrics, Germany
    Anticancer Res 25:2171-5. 2005
    ..We studied the her2 expression in the BM of 105 patients with CK-positive cells present and compared it with results from the primary tumor...